Lupin Limited has informed the Exchange regarding a press release dated November 05, 2025, titled "Lupin Receives EIR from U.S. FDA for its Pithampur Unit-3 Facility".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin Limited has received an Establishment Inspection Report (EIR) from the U.S. FDA for its Pithampur Unit-3 manufacturing facility, dated November 5, 2025. An EIR is issued by the U.S. FDA after it completes and closes an inspection of a drug manufacturing site, confirming the conclusion of the regulatory review. Receiving the EIR typically signals that the facility has satisfactorily addressed any observations raised during the inspection. The Pithampur Unit-3 is one of Lupin's key facilities supplying products to the U.S. market, which is a major revenue contributor for the company.
This is a positive development for Lupin shareholders, as it removes regulatory uncertainty around the Pithampur Unit-3 facility and supports uninterrupted supply of generic drugs to the highly lucrative U.S. market. A clean EIR closure generally boosts investor confidence and can have a mildly positive short-term effect on the stock.